Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Cardio-metabolic and musculo-skeletal characteristics of study population. | Whole Sample | “Normal” Phenotype | Isolated Osteopenia | Isolated Sarcopenia | Osteopenic Sarcopenia | Isolated Adiposity | Osteopenic Adiposity | Sarcopenic Adiposity | Osteosarcopenic Adiposity | | | n = 363 | n = 88 (24.2%) | n = 40 (11.0%) | n = 22 (6.1%) | n = 34 (9.4%) | n = 28 (7.7%) | n = 28 (7.7%) | n = 42 (11.6%) | n = 81 (22.3%) | p-Value: Vitamin D (Calciferol) in ng/mL | 23.5 ± 11.3 | 26.4 ± 13.4 | 26.9 ± 9.7 | 22.2 ± 8.5 | 26.4 ± 10.4 | 20.2 ± 11.1 | 20.5 ± 11.4 | 20.5 ± 8.6 | 21.5 ± 10.5 | <0.005
Source: Results table. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
MRI-Based Phenotyping for Osteosarcopenic Adiposity in Subjects from a Population-Based Cohort
Study design awaiting verification · Geriatrics · 2024
Original publication title
MRI-Based Phenotyping for Osteosarcopenic Adiposity in Subjects from a Population-Based Cohort
© 2024 by the authors.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: STUDY IMPORTANCE QUESTIONS
What is already known about this subject?
Osteosarcopenic adiposity (OSA) is defined as the hazardous triad of osteopenia, sarcopenia, and adiposity causing impaired functionality and metabolic dysregulation.
Ectopic adipogenesis and fat redistribution into the viscera, bone, and muscle tissue have been described as the key components in the co-development and progression of OSA.
The clinical significance of OSA syndrome has been increasingly recognized in recent years, presenting with a higher overall health risk compared to the sum of its individual component traits.
What are the new findings in your manuscript?
Biomarkers of bone, muscle, and fat observed by magnetic resonance imaging may depict the conditions of OSA and may therefore be feasible for body composition phenomapping and cardio-metabolic risk stratification.
Subjects with an OSA phenotype were significantly older, showed the highest grades of skeletal muscle fat, and together with the three other adiposity-containing subgroups also showed the highest BMIs.
The highest prevalence of an impaired glucose tolerance and significantly higher blood pressure, blood dyslipidemia, and hepatic steatosis were found in the OSA subgroup.
How might your results change the direction of research or the focus of clinical practice?
Given the high rate of their comorbidity and high risk of complications, clinical suspicion or diagnosis of either component of the OSA triad should prompt the targeted examination of the other ones.
Recognizing any of the three traits of the OSA complex (e.g., by MRI) may help to guide further diagnostics and induce early holistic and effective intervention and treatments, which might improve health outcomes.
MRI-based phenotyping using biomarkers of bone, muscle, and fat may be feasible especially for body composition phenotyping and may therefore allow for targeted risk stratification and further cardio-metabolic risk assessment in suspected OSA syndrome.
Abstract: Abstract
Objective:
Imaging biomarkers of bone, muscle, and fat by magnetic resonance imaging (MRI) may depict osteopenia, sarcopenia, and adiposity as the three different conditions of osteosarcopenic adiposity (OSA).
Methods:
Subjects from a prospective, population-based case: control study underwent a health assessment and 3 Tesla whole-body MRI scan. Imaging biomarkers of bone (bone marrow fat-fraction (BMFF)), skeletal muscle (skeletal muscle FF (SMFF)), and fat (total adipose tissue (TAT)) were determined. Participants were allocated to one phenotype according to the OSA complex.
Results:
Among 363 participants forming the study cohort, 81 (22.3%, 48.1% males, 62.4 ± 6.9 years) were allocated into the OSA subgroup. Participants with an OSA phenotype were significantly older compared to all remaining subjects and showed the highest grades of SMFF (all p < 0.005). Together with subjects from the osteopenic sarcopenia group, OSA subjects exhibited the highest amounts of BMFF and together with the three other adiposity-containing subgroups also exhibited the highest BMIs. The highest prevalence of an impaired glucose tolerance as well as significantly higher blood pressure, blood dyslipidemia, and hepatic steatosis was found in the OSA subgroup (all p < 0.005).
Conclusions:
MR biomarkers of bone, skeletal muscle and fat are feasible for body composition phenotyping and may allow for targeted risk stratification in suspected OSA syndrome.
Authors’ abstract
STUDY IMPORTANCE QUESTIONS
What is already known about this subject?
Osteosarcopenic adiposity (OSA) is defined as the hazardous triad of osteopenia, sarcopenia, and adiposity causing impaired functionality and metabolic dysregulation.
Ectopic adipogenesis and fat redistribution into the viscera, bone, and muscle tissue have been described as the key components in the co-development and progression of OSA.
The clinical significance of OSA syndrome has been increasingly recognized in recent years, presenting with a higher overall health risk compared to the sum of its individual component traits.
What are the new findings in your manuscript?
Biomarkers of bone, muscle, and fat observed by magnetic resonance imaging may depict the conditions of OSA and may therefore be feasible for body composition phenomapping and cardio-metabolic risk stratification.
Subjects with an OSA phenotype were significantly older, showed the highest grades of skeletal muscle fat, and together with the three other adiposity-containing subgroups also showed the highest BMIs.
The highest prevalence of an impaired glucose tolerance and significantly higher blood pressure, blood dyslipidemia, and hepatic steatosis were found in the OSA subgroup.
How might your results change the direction of research or the focus of clinical practice?
Given the high rate of their comorbidity and high risk of complications, clinical suspicion or diagnosis of either component of the OSA triad should prompt the targeted examination of the other ones.
Recognizing any of the three traits of the OSA complex (e.g., by MRI) may help to guide further diagnostics and induce early holistic and effective intervention and treatments, which might improve health outcomes.
MRI-based phenotyping using biomarkers of bone, muscle, and fat may be feasible especially for body composition phenotyping and may therefore allow for targeted risk stratification and further cardio-metabolic risk assessment in suspected OSA syndrome.
Abstract
Objective:
Imaging biomarkers of bone, muscle, and fat by magnetic resonance imaging (MRI) may depict osteopenia, sarcopenia, and adiposity as the three different conditions of osteosarcopenic adiposity (OSA).
Methods:
Subjects from a prospective, population-based case: control study underwent a health assessment and 3 Tesla whole-body MRI scan. Imaging biomarkers of bone (bone marrow fat-fraction (BMFF)), skeletal muscle (skeletal muscle FF (SMFF)), and fat (total adipose tissue (TAT)) were determined. Participants were allocated to one phenotype according to the OSA complex.
Results:
Among 363 participants forming the study cohort, 81 (22.3%, 48.1% males, 62.4 ± 6.9 years) were allocated into the OSA subgroup. Participants with an OSA phenotype were significantly older compared to all remaining subjects and showed the highest grades of SMFF (all p < 0.005). Together with subjects from the osteopenic sarcopenia group, OSA subjects exhibited the highest amounts of BMFF and together with the three other adiposity-containing subgroups also exhibited the highest BMIs. The highest prevalence of an impaired glucose tolerance as well as significantly higher blood pressure, blood dyslipidemia, and hepatic steatosis was found in the OSA subgroup (all p < 0.005).
Conclusions:
MR biomarkers of bone, skeletal muscle and fat are feasible for body composition phenotyping and may allow for targeted risk stratification in suspected OSA syndrome.
Publication and source details
Original title: MRI-Based Phenotyping for Osteosarcopenic Adiposity in Subjects from a Population-Based Cohort
Elke Maurer; Susanne Rospleszcz; Wolfgang Rathmann; Barbara Thorand; Annette Peters; Christopher L. Schlett; Fabian Bamberg; Lena Sophie Kiefer
Geriatrics · 2024
* Correspondence: lena.kiefer@med.uni-tuebingen.de; Tel.: +49-761-270-61867© 2024 by the authors.2024https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Helmholtz Zentrum München, German Research Center for Environmental HealthBundesministerium für Bildung und Forschung (BMBF)State of BavariaMünchner Zentrum für Gesundheitswissenschaften (MC-Health), Ludwig-Maximilians-Universitä t MünchenGerman Research Foundation (DFG, Deutsche Forschungsgemeinschaft)Siemens HealthineersThe KORA study was initiated and financed by the Helmholtz Zentrum München, German Research Center for Environmental Health, which is funded by the Bundesministerium für Bildung und Forschung (BMBF) and by the State of Bavaria. Furthermore, KORA research was supported within the Münchner Zentrum für Gesundheitswissenschaften (MC-Health), Ludwig-Maximilians-Universitä t München, as part of LMUinnovativ. The KORA MRI sub-study received funding by the German Research Foundation (DFG, Deutsche Forschungsgemeinschaft). The KORA MRI sub-study was supported by an unrestricted research grant from Siemens Healthineers.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T08:28:56.908423+00:00
DOI: 10.3390/geriatrics9060150 · PMC11587111